18/19 - Antithrombotic Agents Flashcards
MOA aspirin
irreversibly block COx1 in platelets which reduces TXA2 production
MOA dipyridamole
elevates cAMP levels which reduce Ca2+ levels which reduces activation of platelets
P2Y12 antagonists
clopidogrel and prasugrel irreversibly inhibit P2Y12
ticagrelor and cangrelor are reversible
contraindication for clopidogrel
omeprazole use
what enzyme activates clopidogrel?
CYP2C19
which P2Y12 antagonists would you use for a patient with intracranial bleeding?
clopidogrel or cangrelor
NOT prasugrel or ticagrelor they have higher bleeding rates but better results
GP IIb and IIIa antagonists
abciximab
eptifibatide
tirofiban
highest risk GPIIb/IIIa antagonist
abciximab
monoclonal antibdoy directed against the GP but also antiinflammatory
MOA vorapaxar
protease activated receptor antagonist
dual antiplatelet therapy
aspirin and P2Y12 antagonist
triple antiplatelet therapy
warfarin
aspirin
clopidogrel
MOA of heparin
accelerates rate of factor Xa inhibition
(only loner heparin molecules) also increases AT induced inhibition of thrombin
for heparin…. clearance ______ as dose increases
decreases
dose-dependent clearance
t1/2 __– as dose increases for heparin
increases
what system is used to monitor heparin
partial thromboplastin time PTT
if bleeding is severe with heparin, what can be administered
protamine sulfate
risk of long term heparin use
osteoporosis
type I v. type II heparin induced thombocytopenia
type 1- of little clinial consequence, first 2-5 days
type 2: immune thrombocytopenia with antibodies generated towards PF4/heparin complex —> venous and arterial thrombosis
more common in women and surgical pts
more common with unfractionated heparin
low molecular weight heparin =
enoxaparin
contraindications for enoxaparin and fondaprinux
renal insufficiency